Pre-Made Eftansomatropin Alfa Biosimilar, Fusion Protein targeting GHR fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting GHBP/GHIP for drug discovery and mechanism of action (MOA) research

Pre-Made Eftansomatropin Alfa Biosimilar, Fusion Protein targeting GHR fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting GHBP/GHIP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eftansomatropin alfa is a potential highly differentiated long-acting recombinant human growth hormone being developed as a more convenient and effective therapy for growth hormone deficiency (GHD). Eftansomatropin alfa contains hGH-hyFc (GX-H9) which is a recombinant human growth hormone prepared by fusing hybrid Fc to human growth hormone hGH. Like endogenous growth hormone, eftansomatropin alfa stimulates the production of insulin-like growth factor 1 (IGF-1) in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth.